22297-32-1

Basic information

• Product Name: 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane
• Synonyms: 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane
• CAS NO: 22297-32-1
• Molecular Weight: 835.351
• Mol File: 22297-32-1.mol

Chemical Properties

• CAS DataBase Reference: 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane(22297-32-1)
• EPA Substance Registry System: 1-[(triphenylcarbinyl)oxy]-2,3-bis[(Z)-octadec-9-enyloxy]propane(22297-32-1)

Safety Data

• Hazardous Substances Data: 22297-32-1(Hazardous Substances Data)

Upstream product

• 35709-09-2 oleyl methanesulfonate 
• 16975-62-5 tritylglycerol 
• 143-28-2 oleoyl alcohol 
• 76-83-5 trityl chloride 
• 6110-54-9 oleyl p-toluenesulfonate 
• 865-47-4 potassium tert-butylate 

Downstream Products

• 6076-41-1 2,3-bis[(Z)-octadec-9-enyloxy]propanol 

Relevant articles and documents

Smart tools and orthogonal click-like reactions onto small unilamellar vesicles

Abstract Click-based reactions were conducted at the surface of small unilamellar vesicles (SUVs) to provide onto-vesicle chemistry with efficient innovative ready-for-use tools. For that purpose, four amphiphilic molecules were designed to insert into bi

LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF

The disclosure concerns new lipid compounds, lipid nanoparticles (LNPs) containing them, and the use of lipid compounds or LNPs for nucleic acid administration. The lipid compounds according to the disclosure comprise at least one terminal radical of formula (I): *-NH-CX-(NH)n-A (I), wherein: -*- Represents a simple bond binding said radical of formula (I), directly or indirectly, to a lipophilic or hydrophobic tail group in C10 to C55; - n is 0 or 1; - X is an oxygen atom or a sulfur atom, and - A represents an unsaturated heterocyclic radical with 5 or 6 chains optionally substituted or a heteroaromatic cyclic radical with 5 or 6 links, both containing at least one nitrogen atom; or one of the pharmaceutically acceptable salts of said radical of formula (I); and said compound being in all possible racemic isomers, enantiomers and diastereoisomers.

Nucleic acid medicine delivery system and application thereof

The invention discloses a nucleic acid medicine delivery system and application thereof. The system consists of a neutral base lipid carrier and metal salt, wherein the structure of the neutral base lipid carrier is shown as a formula I. In addition, the delivery system provided by the invention also comprises metal salt. The experiment proves that through the existence of metal ion, the silent activity of the nucleic acid medicine can be effectively improved; the effective transportation of the nucleic acid medicine in the cells and in the body can be realized. The chemical modification methods such as D,L-isonucleoside modification, deoxyinosine modification, peptide conjugation modification and phosphorylation modification are jointly used for nucleic acid delivery system study; the advantages and rules of the nucleic acid delivery in a composite modification mode are sufficiently explored; the modification strategies are used in the nucleic acid medicine study. Study proves that the products obtained through chemical modification are more applicable to the system; in addition, the advantages of stable physicochemical properties, good bioactivity and good membrane permeability and the like are realized. The nucleic acid medicine delivery system provided by the invention has wide application prospects in the gene treatment field. The formula is shown in the description.

Supramolecular assemblies of novel aminonucleoside phospholipids and their bonding to nucleic acids

A novel class of aminonucleoside phospholipids has been developed. These molecules could spontaneously assemble into supramolecular structures including multilamellar organization, hydrogels, superhelical strands, and vesicles. Their ability to bind to DNA by hydrogen bonding and π-π stacking interactions was investigated by many means. This journal is

Drug composition containing nucleic acid copolymer

This invention has for its object to insure an effective utilization of single-stranded nucleic acid copolymers, particularly poly(adenylic acid-uridylic acid), and to provide a pharmaceutical composition having antitumor activity. The invention typic

A metal-chelating lipid for 2D protein crystallization via coordination of surface histidines

Two-dimensional protein crystallization on lipid monolayers is becoming a powerful technique for structure determination as well as materials applications. However, progress has been hindered by the requirement of a unique affinity lipid for each new protein of interest. Metal ion coordination by surface-accessible histidine side chains provides a convenient and general method for targeting of proteins to surfaces. Here we present the synthesis and characterization of a metal-chelating lipid which has been designed to target proteins to Langmuir monolayers and promote their two-dimensional crystallization based on histidine coordination. The lipid utilizes the metal chelator iminodiacetate (IDA) as the hydrophilic headgroup and contains unsaturated, oleyl tails to provide the fluidity necessary for two-dimensional protein crystallization. The lipid is shown to bind copper from the subphase strongly when incorporated in Langmuir monolayers. In addition, it is possible to form copper-containing monolayers by spreading the premetalated lipid on the subphase in the absence of copper. Fluorescence microscopy reveals the binding and crystallization of the protein streptavidin, promoted by the simultaneous coordination of two surface-accessible histidine side chains to the IDA-Cu lipid.